eXagenBC™ is the only genomic marker test submitted for 510(k) clearance that uses fluorescent in situ hybridization (FISH) technology to assess the likelihood of breast cancer distant recurrence (metastasis) in women with newly diagnosed, early stage invasive ductal breast cancer. eXagenBC is currently available as Investigational Use Only. The performance characteristics of this product have not been established.